Navigation
banner

Infectious Diseases Summit 2017

2018-04-232017-06-132017-05-13
Register 3 for the price of 2 with the coupon code rcdvb!


MENTORS
Kevin Gilligan

Kevin Gilligan
Senior Scientific Advisor
ClinicalRM
Kevin Gilligan
Senior Scientific Advisor
ClinicalRM
 
About Mentor:

Kevin J. Gilligan, Ph.D. is a virologist and emerging disease expert with over 30 years of experience in academia, government and industry developing vaccines, drugs and diagnostics to address public health issues related to global emerging disease.  Dr. Gilligan earned his Ph.D. in the Dept. pf Microbiology and Immunology at the University of North Carolina at Chapel Hill in 1990.  As a National Research Council Fellow working at Ft. Detrick, Dr. Gilligan was the first to demonstrate acquired immunity to Ebola virus via vaccination in a guinea pig animal model.  Dr. Gilligan recently left HHS/BARDA (U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority), where he was Branch Chief for drugs and therapeutics in the Influenza division. Dr. Gilligan has since joined ClinicalRM as Senior Scientific Advisor.

Kathrin Jansen

Kathrin Jansen
SVP and Head of Vaccine Research & Development
Pfizer
Kathrin Jansen
SVP and Head of Vaccine Research & Development
Pfizer
 
About Mentor:

Kathrin U. Jansen, Ph.D. is a Senior Vice President at Pfizer’s Pearl River, NY campus. Dr. Jansen has responsibility for the scientific management of vaccine research and early development as well as management responsibilities for all vaccines clinical and diagnostic testing.

Dr. Jansen received her doctoral degree in Microbiology, Biochemistry & Genetics from Phillips Universitat, Marburg, Germany, in 1984. Following completion of her formal training and postdoctoral work at the Institute for Mikrobiologie in Marburg, Dr. Jansen continued her training with Professor G.P. Hess at Cornell University working on the expression of the acetylcholine receptor in yeast for structural and functional studies. She then joined the Glaxo Institute for Molecular Biology in Geneva, Switzerland where she focused on basic studies of a receptor believed to be a drug target to treat allergies.

In 1992, Dr. Jansen moved to the Merck Research Laboratories. During the following 12 years, she directed a number of vaccine research efforts, including Merck’s novel bacterial vaccine programs. Dr. Jansen initiated Merck’s vaccine program for the prevention of human papillomavirus infection (HPV). She played a central role in the vaccine’s design, the development of novel HPV clinical diagnostic assays, clinical trial designs, the study of the virus’ epidemiology, the successful completion of the vaccine’s proof-of-concept trial and the entry of the vaccine into phase 2/3 clinical trials. Her efforts led to the licensure of the world’s first cervical cancer vaccine (Gardasil®).

Dr. Jansen left Merck in October 2004 to join VaxGen as Chief Scientific Officer and Senior Vice President for Research and Development with responsibility for VaxGen’s late stage development anthrax and smallpox vaccine programs.

In 2006, Dr. Jansen joined Wyeth (now Pfizer) as a Senior Vice President to lead the vaccine research (with focus on infectious disease targets), early development and clinical testing groups. In this capacity, she and colleagues at Pfizer supported the licensure of Prevnar 13 (infant indication), licensure application of Prevnar 13 (adult indication), as well as the conduct of the CAPITA trial. In addition, the work of her group and colleagues at Pfizer led to the successful outcomes of the proof-of-concept phase 2 clinical evaluation of the Neisseria meningitidis serogroup B vaccine and phase 1 trial for Staphylococcus aureus.

Dr. Jansen was appointed an Adjunct Professor at the University of Pennsylvania – School of Medicine in 2010. Dr. Jansen brings a recognized series of accomplishments, as well as an established international reputation in vaccine discovery research and development

Ken Rosenthal

Ken Rosenthal
Professor of Biomedical Sciences
Roseman University of Health Sciences
Ken Rosenthal
Professor of Biomedical Sciences
Roseman University of Health Sciences
 
About Mentor:

Ken S. Rosenthal, Ph.D. received his B.S. in Chemistry from the University of Delaware, his M.A. and Ph.D. in Biochemistry from the University of Illinois, and was an American Cancer Society post doctoral fellow with Jack Strominger at the Dana Farber Cancer Institute, Harvard Medical School. KSR has received funding from the N.I.H., the American Cancer Society, and the Pharmaceutical and Biotech Industry for the development and study of vaccines for viruses, cancer, and autoimmune diseases, immune-modulators, antibacterial and antiviral drugs, as well as mechanisms of pathogenesis of herpes simplex virus.  

With Dr. Dan Zimmerman of CEL-SCI, he is a co-holder of patents for LEAPS anti-herpes simplex virus vaccines and has developed LEAPS vaccines to treat cancer and autoimmune diseases. KSR has been an organizer and presenter at each of the GTCBIO Vaccines:  All Things Considered Meetings and Section Editor for ‘Basic Microbiology and Immunology’ in the journal, Infectious Diseases in Clinical Practice. 

He has been editor and a primary author of MEDICAL MICROBIOLOGY, 1st through 8th editions, (2017), a successful textbook translated into many languages, and also author of RAPID REVIEWS OF MICROBIOLOGY AND IMMUNOLOGY, 1st through 3rd editions (2010), REVIEW OF MEDICAL MICROBIOLOGY (2005), and MEDICAL MICROBOLOGY AND IMMUNOLOGY FLASH CARDS, (2005, 2009,  2017). KSR is a Master Teacher of the NEOMED Master Teacher’s Guild.

At NEOMED, his medical students chose him as Hooder (2011, 2012, 2014) and M2 Teacher of the Year, 2015 and for the Gender Equity Award, 2012. His pharmacy students chose him as Phi Lambda Sigma Honorary Member, 2015. He is also the primary developer of MEDCAMP, CAMPMED, DISCOVERMED and other pre-college science education programs delivered in Ohio and Las Vegas, NV.   He is currently Professor and Director of Microbiology and Immunology at Roseman University of Health Sciences working to create a new college of medicine.

David Vaughn

David Vaughn
Senior Vaccine Development Leader for Influenza and Dengue Vaccines, GSK Vaccines Research and Development
GSK
David Vaughn
Senior Vaccine Development Leader for Influenza and Dengue Vaccines, GSK Vaccines Research and Development
GSK
 
About Mentor:

David W. Vaughn, M.D., M.P.H. joined GSK Vaccines in 2007 with roles as the Clinical Lead for Pandemic Influenza Vaccines, Head of Global Vaccines Clinical Laboratories, Head of External R&D, North America, and currently as the Senior Vaccine Development Leader for Influenza and Dengue Vaccines also working in support of GSK’s proposal to establish a Biopreparedness Organization. This follows a 21-year career with the U.S. Army where he served as the Chief of the Department of Pediatrics in Nurnberg, Germany, Chief of the Department of Virology at the Armed Forces Research of Medical Sciences in Bangkok, Thailand and the Chief of the Department of Virus Diseases, Walter Reed Army Institute of Research leading efforts to develop vaccines against dengue, Japanese encephalitis, hepatitis E, and adenovirus. His final position in the military was as the Director of the U.S. Military Infectious Diseases Research Program. Dr. Vaughn holds B.A. degrees in Chemistry and Psychology from Seattle Pacific University, an M.D. degree from St. Louis University School of Medicine, Pediatrics certification following training at Indiana University School of Medicine, and an M.P.H. from the Johns Hopkins University School of Public Health and Hygiene.

Robert Walker

Robert Walker
Director, Division of Clinical Development
BARDA, HHS
Robert Walker
Director, Division of Clinical Development
BARDA, HHS
 
About Mentor:

Dr. Walker is the (Acting) Chief Medical Officer and Director of the Division of Clinical Development (DCD) in the Biomedical Advancement Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The DCD manages the Clinical Studies Network and is responsible for oversight of the coordination, execution, and analysis of interventional clinical studies funded by BARDA. Dr. Walker joined BARDA in 2014, and oversees a diverse portfolio of projects. Prior to joining BARDA, Dr. Walker was chief medical officer at Nuron Biotech, vice president of clinical development at Aeras, and vice president of clinical development and medical and scientific affairs at MedImmune, Inc. Before working in biotech, Dr. Walker was a clinical investigator at the National Institute of Allergy and Infectious Diseases and an attending physician in Critical Care Medicine at the National Institutes of Health. 

Dan Zimmerman

Dan Zimmerman
Senior Vice President Research and Development, Cellular Immunology
CEL-SCI Corporation
Dan Zimmerman
Senior Vice President Research and Development, Cellular Immunology
CEL-SCI Corporation
 
About Mentor:

Daniel H. Zimmerman, Ph.D. has been CEL-SCI’s Senior Vice President of Research, Cellular Immunology since June 1998.  He joined CEL-SCI in January 1996 as its Vice President of Research, Cellular Immunology.  Dr. Zimmerman founded CELL-MED, Inc. and was its president from 1987-1995.  From 1973 to 1987 Dr. Zimmerman served in various positions at Electronucleonics, Inc. including Scientist, Senior Scientist, Technical Director and Program Manager.  He has also been a guest worker at NIH and NCI for over 30 years in support of various collaborations with NIH or NCI scientists.  From 1969-1973, Dr. Zimmerman was a Senior Staff Fellow at NIH.  He has also lectured and taught as an adjunct professor at several local colleges and universities.

Dr. Zimmerman has an extensive background in the biotechnology industry including research and development, product transfer and clinical practice with expertise in innate and inductive immunology.  He has over 30 years industry experience in researching and developing products for diagnosis, immunological status monitoring and vaccines.  He has successfully developed commercial diagnostic products for Herpes Simplex Virus, Hepatitis B and HIV.  He has been awarded grants and contracts from NIH and DOD in these areas as well as innate immunity and autoimmune diseases, including several phase I and phase II SBIR grants and currently is PI on a SBIR phase I award for PGIA arthritis model of rheumatoid arthritis. He has seen the SBIR program evolve to include the IND enabling studies now currently being used and change in emphasis from hypothesis oriented grants applications to more of a development approach.  Previously he conducted basic research in T-cell immunology starting from the late 60's at NIH.  He has been a study section reviewer on over a dozen NIH study sections.  He has been a speaker in numerous conferences, served on the organization committee of vaccine and cytokine conferences and chairman of several vaccine conferences.  He has talked on scientific issue and related issues such as funding, product management, technology transfer and need for changes

Dr. Zimmerman received a B.S. degree from Emory and Henry College (1963) and a M.S. degree in Zoology from the University of Florida (1966).  He holds a Ph.D. in Biochemistry from the University of Florida’s College of Medicine (1969).  He was a NDEA fellow at the University of Florida.  He received several awards from College and Graduate school.  His strong technical background, desire, and interest in technologies such as recombinant DNA, synthetic peptides, mechanisms of cell activation, and subsequent events in the immune responses provide him the experience and perspective with which he has guided product development programs.  Dr. Zimmerman has over 50 publications in peer reviewed journals and US patents in the fields of immunology, virology, L.E.A.P.S.TM and CEL-1000 technology.  Additional patent applications are under review.  In May 2009 he was awarded the William and Martha DeFriece award by Emory and Henry College at its commencement for outstanding alumni or Faculty for his work in the sciences.